Table 4 Markers of coagulation at baseline (all patients on aspirin) and after 12 months continuing on aspirin or randomized to clopidogrel
From: Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment
ASPIRIN (n = 145) | CLOPIDOGREL (n = 131) | ||||||
|---|---|---|---|---|---|---|---|
Baseline | 12 months | p1 | Baseline | 12 months | p2 | Δ p | |
F1+2 (pmol/L) | 216 (157, 282) | 196 (142, 261) | 0.029 | 201 (149, 279) | 205 (158, 340) | 0.298 | 0.023 |
D-dimer (ng/ml) | 424 (271, 642) | 434 (309, 661) | 0.189 | 399 (284, 603) | 409 (277, 583) | 0.405 | 0.129 |
ETP (nM·min) | 1502 (1308, 1626) | 1397 (1148, 1571) | 0.003 | 1492 (1281, 1676) | 1366 (1165, 1584) | <0.001 | 0.687 |
sTF (pg/ml) | 139 (91, 191) | 143 (95, 206) | 0.029 | 158* (120, 218) | 154 (118, 222) | 0.384 | 0.042† |
TFPI (free) (ng/ml) | 15.3 (12.3, 17.9) | 16.7 (13.0, 20.6) | <0.001 | 14.4 (11.4, 18.1) | 15.3 (11.7, 18.6) | 0.035 | 0.163 |
TFPI (total) (ng/ml) | 68.4 (58.7, 76.6) | 66.4 (58.6, 74.4) | 0.190 | 66.1 (58.1, 76.6) | 65.1 (57.9, 75.0) | 0.130 | 0.864 |